tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment
PremiumCompany AnnouncementsLarimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment
3M ago
Buy Rating for Larimar Therapeutics: Optimism in Frataxin Replacement Therapy Despite Safety Concerns
Premium
Ratings
Buy Rating for Larimar Therapeutics: Optimism in Frataxin Replacement Therapy Despite Safety Concerns
3M ago
Positive Outlook for Larimar Therapeutics Amidst Regulatory Challenges: Buy Rating Justified
Premium
Ratings
Positive Outlook for Larimar Therapeutics Amidst Regulatory Challenges: Buy Rating Justified
3M ago
3 Best Stocks to Buy Now, 10/6/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 10/6/2025, According to Top Analysts
4M ago
Buy Rating for Larimar Therapeutics: Promising Efficacy of Nomla in Friedreich’s Ataxia Amidst Anaphylaxis Concerns
Premium
Ratings
Buy Rating for Larimar Therapeutics: Promising Efficacy of Nomla in Friedreich’s Ataxia Amidst Anaphylaxis Concerns
4M ago
Larimar Therapeutics price target lowered to $21 from $26 at Oppenheimer
Premium
The Fly
Larimar Therapeutics price target lowered to $21 from $26 at Oppenheimer
4M ago
EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
PremiumThe FlyEA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
5M ago
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Data and Safety Adjustments
Premium
Ratings
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Data and Safety Adjustments
5M ago
Larimar Therapeutics Announces Positive Study Results
Premium
Company Announcements
Larimar Therapeutics Announces Positive Study Results
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100